Date: 2011-02-28
Type of information: Series A financing round
Company: Arsanis (USA - MA)
Investors: OrbiMed Advisors (USA - NY) Polaris Venture Partners (USA - MA) SV Life Sciences (UK - USA)
Amount: $10 million
Funding type: series A financing round
Planned used: Arsanis was founded in the fall of 2010 by Dr. Eszter Nagy (former SVP of Research at Intercell),Dr. Tillman Gerngross (Co-founder and CEO of Adimab, and Co-founder and CSO of GlycoFi, a wholly owned subsidiary of Merck & Co. since 2006) and Errik Anderson (Co-founder and COO of Adimab) who bring together expertise in monoclonal antibody discovery, infectious disease biology and commercializing innovation. The company will initiate its operations in Vienna, Austria. Proceeds from the initial financing will be used to advance several pre-clinical proof-of-concept programs in the anti-microbial infectious disease area.
Others: * On February 28, 2011, Arsanis announced the closing of a Series A financing with a total funding amount of $10 million. The financing involved equal contributions from OrbiMed Advisors, Polaris Venture Partners and SV Life
Sciences. Managing Partners, Carl Gordon, Terry McGuire and Mike Ross joined the founders on Arsanis’
Board of Directors.
Therapeutic area: Infectious diseases
